|
30 Companies |
|
20 Products |
|
20 Products |
|
12 Mechanisms of Action |
|
0 Trials |
|
103 News |
|
| «123» |
- Trial termination: Hyperglycemia in Surgical Infections (clinicaltrials.gov) - May 1, 2014
P=N/A, N=5, Terminated, Sponsor: The University of Texas Health Science Center, Houston
Completed --> Terminated; Difficulty in enrolling eligible patients
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P1/2 trial: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Apr 26, 2014
P1/2, N=4, Not yet recruiting, Sponsor: James Chodosh, MD, MPH
- |||| Lytixar (LTX-109) / Lytix
Trial completion: A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo (clinicaltrials.gov) - Apr 24, 2014
P2, N=210, Completed, Sponsor: Lytix Biopharma AS
Completed --> Terminated; Difficulty in enrolling eligible patients Recruiting --> Completed
- ||| AMG 108 / AstraZeneca
Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Apr 17, 2014
P2a, N=100, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed N=150 --> 100
- ||||| Privigen (human immune globulin intravenous 10%) / CSL Behring
New P2 trial: INSTINCT: Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial (clinicaltrials.gov) - Apr 9, 2014
P2, N=100, Recruiting, Sponsor: Anders Perner
- Enrollment change: Hyperglycemia in Surgical Infections (clinicaltrials.gov) - Mar 31, 2014
P=N/A, N=17, Completed, Sponsor: The University of Texas Health Science Center, Houston
N=150 --> 100 N=100 --> 17
- | Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
New P3 trial: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Mar 16, 2014
P3, N=0, Not yet recruiting, Sponsor: Ferrer Internacional S.A.
- | Arbelic (telavancin) / Cumberland
Trial completion, Gram positive: ATLAS2: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus (clinicaltrials.gov) - Feb 22, 2014
P3, N=1035, Completed, Sponsor: Theravance, Inc.
N=100 --> 17 Recruiting --> Completed
- | Arbelic (telavancin) / Cumberland
Trial completion, Gram positive: ATLAS1: Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus (clinicaltrials.gov) - Feb 22, 2014
P3, N=862, Completed, Sponsor: Theravance, Inc.
Recruiting --> Completed Recruiting --> Completed
- phenoxymethylpenicillin / Generic mfg., doxycycline / Generic mfg., amoxicillin / Generic mfg.
Enrollment closed: NorTick_EM: Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice (clinicaltrials.gov) - Feb 12, 2014
P4, N=225, Active, not recruiting, Sponsor: Morten Lindbaek
Recruiting --> Completed Recruiting --> Active, not recruiting
- amoxicillin / Generic mfg.
Trial termination, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Not yet recruiting --> Terminated; Insufficient number of inclusion
- amoxicillin / Generic mfg.
Trial initiation date, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - H
Not yet recruiting --> Terminated; Insufficient number of inclusion Initiation date: Feb 2010 --> Sep 2010
- amoxicillin / Generic mfg.
Enrollment change, Head-to-Head: Short Course of Amoxicillin for Erysipelas (clinicaltrials.gov) - Feb 5, 2014
P4, N=10, Terminated, Sponsor: Assistance Publique - H
Initiation date: Feb 2010 --> Sep 2010 N=646 --> 10
- Kineret (anakinra) / SOBI
Enrollment closed: Anakinra in Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 2, 2014
P2, N=20, Active, not recruiting, Sponsor: University of Athens
N=646 --> 10 Recruiting --> Active, not recruiting
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
- Kepivance (palifermin) / SOBI, Amgen
Enrollment open: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | flucloxacillin sodium / Generic mfg.
New P4 trial: DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) - Jan 8, 2014
P4, N=396, Not yet recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- drospirenone/ethinyl estradiol / Generic mfg.
Enrollment change: A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS (clinicaltrials.gov) - Dec 1, 2013
P2, N=4, Terminated, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting N=40 --> 4
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
New P3 trial: Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Nov 13, 2013
P3, N=660, Not yet recruiting, Sponsor: Melinta Therapeutics, Inc.
- | mupirocin / Generic mfg.
Trial completion: PRIMO: A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection (clinicaltrials.gov) - Sep 24, 2013
P3, N=350, Completed, Sponsor: Los Angeles Biomedical Research Institute
N=40 --> 4 Active, not recruiting --> Completed
- ||||||| Trial completion: Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo (clinicaltrials.gov) - Sep 2, 2013
P2/3, N=328, Completed, Sponsor: Galderma
Active, not recruiting --> Completed Recruiting --> Completed
- Kineret (anakinra) / SOBI
Trial completion: Anakinra as a Treatment for Hydradenitis Suppurativa (clinicaltrials.gov) - Jul 4, 2013
P2, N=6, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Completed
- |||| AMG 108 / AstraZeneca
Enrollment open: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Jun 12, 2013
P2a, N=100, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Stelara (ustekinumab) / J&J
Enrollment closed: A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (clinicaltrials.gov) - Jun 12, 2013
P2, N=20, Active, not recruiting, Sponsor: University Medical Centre Groningen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial withdrawal: Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) (clinicaltrials.gov) - Apr 24, 2013
P2, N=0, Withdrawn, Sponsor: Loyola University
Recruiting --> Active, not recruiting Terminated --> Withdrawn
- ||||| AMG 108 / AstraZeneca
New P2a trial: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Apr 22, 2013
P2a, N=100, Recruiting, Sponsor: AstraZeneca
- mupirocin / Generic mfg.
Trial initiation date: HOME2DS: Individualized vs. Household MRSA Decolonization (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=600, Enrolling by invitation, Sponsor: Washington University School of Medicine
Terminated --> Withdrawn Initiation date: Jan 2013 --> Apr 2013
- mupirocin / Generic mfg.
Clinical: HOME2DS: Individualized vs. Household MRSA Decolonization (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=600, Enrolling by invitation, Sponsor: Washington University School of Medicine
- |||||||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
New P3 trial: Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Mar 13, 2013
P3, N=660, Recruiting, Sponsor: Melinta Therapeutics, Inc.
- ||||||| Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
Trial completion: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Mar 5, 2013
P3, N=465, Completed, Sponsor: Ferrer Internacional S.A.
Initiation date: Jan 2013 --> Apr 2013 Recruiting --> Completed
- ||||| Lytixar (LTX-109) / Lytix
New P2 trial: A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo (clinicaltrials.gov) - Feb 28, 2013
P2, N=210, Completed, Sponsor: Lytix Biopharma AS
- ||| ceftaroline fosamil / Generic mfg.
Trial completion, Gram positive, Gram negative: CERBERUS: Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia (clinicaltrials.gov) - Jan 31, 2013
P=N/A, N=3000, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Completed
- Cubicin (daptomycin) / Merck (MSD)
Trial withdrawal: Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation (clinicaltrials.gov) - Dec 27, 2012
P=N/A, N=0, Withdrawn, Sponsor: Federico II University
Recruiting --> Completed Recruiting --> Withdrawn
- Cubicin (daptomycin) / Merck (MSD)
Enrollment change: Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation (clinicaltrials.gov) - Dec 27, 2012
P=N/A, N=0, Withdrawn, Sponsor: Federico II University
Recruiting --> Withdrawn N=100 --> 0
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Dec 17, 2012
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
N=100 --> 0 Not yet recruiting --> Recruiting
- |||| Trial completion: A Complicated Skin and Soft-tissue Infection Patient Registry (clinicaltrials.gov) - Nov 28, 2012
P4, N=1081, Completed, Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=134, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Completed Recruiting --> Completed
- | Stelara (ustekinumab) / J&J
New P2 trial: A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (clinicaltrials.gov) - Oct 9, 2012
P2, N=20, Active, not recruiting, Sponsor: University Medical Centre Groningen
- |||| Cubicin (daptomycin) / Merck (MSD)
Trial completion, HEOR: DAPHEOR1006: Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA (clinicaltrials.gov) - Oct 8, 2012
P4, N=250, Completed, Sponsor: Cubist Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Sep 27, 2012
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- Kineret (anakinra) / SOBI
Trial initiation date: Anakinra as a Treatment for Hydradenitis Suppurativa (clinicaltrials.gov) - Sep 5, 2012
P2, N=6, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Initiation date: Jul 2012 --> Oct 2012
- |||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Trial completion: A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study (clinicaltrials.gov) - Sep 4, 2012
P2, N=200, Completed, Sponsor: Trius Therapeutics, Inc.
Initiation date: Jul 2012 --> Oct 2012 Active, not recruiting --> Completed
- |||||||||| New P2/3 trial: Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo (clinicaltrials.gov) - Aug 19, 2012
P2/3, N=328, Completed, Sponsor: Galderma
- ||||| Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
Trial initiation date: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Jul 24, 2012
P3, N=465, Completed, Sponsor: Ferrer Internacional S.A.
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Mar 2012
- ||||| Zeftera (ceftobiprole) / Basilea
Enrollment change: Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections (clinicaltrials.gov) - Jul 24, 2012
P3, N=828, Completed, Sponsor: Basilea Pharmaceutica
Initiation date: Oct 2011 --> Mar 2012 N=76 --> 828
- phenoxymethylpenicillin / Generic mfg.
Trial completion: PATCH1: RCT to Investigate if Prophylactic Antibiotics Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (clinicaltrials.gov) - Jul 22, 2012
P4, N=274, Completed, Sponsor: University of Nottingham
N=76 --> 828 Active, not recruiting --> Completed
- doxycycline / Generic mfg.
Enrollment change: Duration of Antibiotic Treatment of Erythema Migrans (clinicaltrials.gov) - Jul 17, 2012
P=N/A, N=306, Completed, Sponsor: University Medical Centre Ljubljana
Active, not recruiting --> Completed N=405 --> 306
- |||||||||| Humira (adalimumab) / AbbVie
New P3 trial: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 8, 2012
P3, N=540, Enrolling by invitation, Sponsor: AbbVie (prior sponsor, Abbott)
- |||| brilacidin (PMX-30063) / Innovation Pharma
Trial completion: Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus (clinicaltrials.gov) - May 15, 2012
P2, N=215, Completed, Sponsor: PolyMedix, Inc.
N=405 --> 306 Recruiting --> Completed
- | Trial completion: Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients (clinicaltrials.gov) - Apr 24, 2012
P2, N=32, Completed, Sponsor: Foamix Ltd.
Recruiting --> Completed Recruiting --> Completed